Skip to main content

Moderna (NASDAQ:MRNA) Stock Rating Reaffirmed by Piper Sandler

Last updated on Wednesday, April 21, 2021 | 2021 MarketBeat

Moderna (NASDAQ:MRNA)'s stock had its "overweight" rating reissued by Piper Sandler in a research report issued to clients and investors on Wednesday, Benzinga reports. They presently have a $234.00 price target on the stock, up from their prior price target of $208.00. Piper Sandler's price objective points to a potential upside of 49.25% from the company's current price.

A number of other research analysts also recently weighed in on the company. Brookline Capital Management upped their target price on Moderna from $180.00 to $205.00 and gave the stock a "buy" rating in a report on Thursday, March 4th. Bank of America restated a "sell" rating and issued a $140.00 price target on shares of Moderna in a research note on Friday, February 26th. Wells Fargo & Company upped their price objective on Moderna from $129.00 to $145.00 and gave the company an "equal weight" rating in a research report on Monday, February 1st. Chardan Capital upped their price objective on Moderna from $107.00 to $182.00 and gave the company a "buy" rating in a research report on Monday, March 8th. Finally, SVB Leerink reissued a "sell" rating on shares of Moderna in a report on Sunday. Three research analysts have rated the stock with a sell rating, seven have issued a hold rating and nine have given a buy rating to the company's stock. The company presently has a consensus rating of "Hold" and a consensus target price of $152.22.

MRNA opened at $156.78 on Wednesday. The business has a 50 day simple moving average of $140.09 and a two-hundred day simple moving average of $125.54. The firm has a market capitalization of $62.79 billion, a price-to-earnings ratio of -96.78, a PEG ratio of 0.53 and a beta of 1.73. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.43 and a quick ratio of 2.43. Moderna has a one year low of $43.11 and a one year high of $189.26.

Moderna (NASDAQ:MRNA) last posted its earnings results on Thursday, February 25th. The company reported ($0.69) earnings per share for the quarter, missing analysts' consensus estimates of ($0.25) by ($0.44). Moderna had a negative return on equity of 28.11% and a negative net margin of 242.73%. The firm had revenue of $570.80 million for the quarter, compared to analysts' expectations of $279.41 million. During the same quarter last year, the company posted ($0.37) EPS. The firm's revenue was up 3948.2% on a year-over-year basis. As a group, sell-side analysts expect that Moderna will post -1.5 EPS for the current fiscal year.

In other news, insider Tal Zvi Zaks sold 1,199 shares of the firm's stock in a transaction on Monday, March 22nd. The shares were sold at an average price of $144.82, for a total value of $173,639.18. Following the sale, the insider now directly owns 1,199 shares in the company, valued at approximately $173,639.18. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Stephane Bancel sold 11,046 shares of the firm's stock in a transaction on Friday, January 22nd. The shares were sold at an average price of $131.81, for a total transaction of $1,455,973.26. Following the completion of the sale, the chief executive officer now owns 6,483,868 shares in the company, valued at $854,638,641.08. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 5,704,212 shares of company stock valued at $831,464,033. 29.20% of the stock is owned by corporate insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Black Swift Group LLC purchased a new position in Moderna during the 4th quarter worth $26,000. Catalyst Capital Advisors LLC purchased a new stake in shares of Moderna in the fourth quarter valued at about $29,000. Clearview Wealth Advisors LLC purchased a new stake in shares of Moderna in the fourth quarter valued at about $32,000. Jeppson Wealth Management LLC purchased a new stake in shares of Moderna in the third quarter valued at about $33,000. Finally, Park Capital Group purchased a new stake in shares of Moderna in the fourth quarter valued at about $33,000. 51.21% of the stock is currently owned by hedge funds and other institutional investors.

Moderna Company Profile

Moderna, Inc, a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics.

Featured Story: How dollar cost averaging works

Analyst Recommendations for Moderna (NASDAQ:MRNA)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Featured Article: What is Cost of Goods Sold (COGS)?

7 Forever Stocks That Are Never Bad to Buy

Investors thought 2021 would be a less volatile year. That narrative has run into some problems. Sure, all the major indexes are up for the year. And that’s despite the NASDAQ’s gut-wrenching 10% drop in March.

But many investors don’t feel much like celebrating. In fact, many are concerned about the liquidity that continues to be pumped into the stock market. In 2020, the pandemic flooded the economy with $6 trillion dollars of stimulus.

However, in the last few months, the Federal Reserve has introduced another $6 trillion into the economy. We would have stopped counting, but the math is pretty easy. It’s $12.3 trillion that has flooded into the economy.

Eventually, this is going to end badly. But timing the market is an imperfect science particularly when many investors are enjoying the game.

Fortunately, there’s a way to safeguard your portfolio without abandoning equities. That has to do with investing in forever stocks. Forever stocks aren’t magic beans. They don’t go up forever. But they are stocks that have stood the test of time. And investing in these stocks will keep your portfolio heading in the right direction.

With that in mind, we’ve put together this special presentation that showcases seven of these forever stocks. These are all stocks that are household names, but that’s kind of the point. You don’t need special knowledge. You just have to recognize that these are companies that consistently do right by their shareholders.

View the "7 Forever Stocks That Are Never Bad to Buy".

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.